Newborn and Infant Nursing Reviews
Volume 8, Issue 3 , Pages 136-143 , September 2008

Preventing Transmission of the Human Immunodeficiency Virus From Mothers to Infants: Review of Research and Guidelines for Practice

  • Lee Di Fonzo, RN, MScN

      Affiliations

    • Corresponding Author InformationAddress correspondence to Lee Di Fonzo, RN, MScN, Sunnybrook Health Sciences Centre, Womens College Hospital, 76 Grenville St, Toronto, Ontario, Canada M5S 1B2.
    • ,
  • Davina Douglas, RN, MScN
    • ,
  • Carla Findlater, Pharm D

References 

  1. Isaacs D, Moxon ER. Viral infections. In:  Isaacs D,  Moxon ER editor. Handbook of neonatal infections: a practical guide. China: WB Saunders; 2000;p. 302–358
  2. Janeway C. Failures of host defense mechanisms. In: 4th ed. Immunology: the immune system in health and disease. 65(10):New York: Current Biology Publications Physician; 1999;p. 2049
  3. Levinson W. Human immunodeficiency virus. In:  Levinson W editors. Review of medical microbiology and immunology. 9th ed.. United States: Lange Medical Books/McGraw Hill; 2006;p. 321–329
  4. CDC . Advancing HIV prevention: new strategies for a changing epidemic—United States. J Am Med Assoc. 2003;289:2493–2495
  5. CDC . Reduction in perinatal transmission of human immunodeficiency virus—United States, 1985-2006. MMWR Morb Mortal Wkly Rep. 2006;21:592–597
  6. CDC . Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR Morb Mortal Wkly Rep. 2006;55(RR14):1–27
  7. UNAIDS (2007). Press release Geneva, 20 November 2007. Global HIV prevalence has leveled off; AIDS is among the leading cause of death globally and remains the primary cause of death in Africa. www.unaids.org downloaded January 23, 2008.
  8. Krist AH, Crawford-Faucher A. Management of newborns exposed to maternal HIV infection. Am Family. 2002;2049–2056
  9. Keenan-Lindsay K, Yudin MH. HIV screening in pregnancy. SOGC Clin Pract Guide. 2006;1103–1107
  10. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose 15 intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189–198
  11. Public Health Agency of Canada, (2006). HIV and AIDS in Canada; surveillance report to December 31, 2006. Ottawa: surveillance and risk assessment division, public health agency of Canada, 2007.
  12. Lindegren ML, Byers RH, Thomas P. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA. 1999;531–538
  13. van Schalkwyk J, Chaworth-Musters T, Mann E, et al. Time to HIV suppression with HAART in pregnancy. Can J Infect Dis Med Biol. 2007;18(supplement B:32B):Abstract 0068
  14. Nahmias AJ, Kourtis AP. The great balancing acts: the pregnant woman, placenta, fetus, and infectious agents. Clin Perinatol. 1997;24:497
  15. Kourtis AP, Butlerys M, Nesheim SR, Lee FK. Understanding the timing of HIV transmission from mother to infant. JAMA. 2001;709–712
  16. Mofenson LM. Tale of two epidemics—the continuing challenge of preventing mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2003;187:721–724
  17. Duliège AM, Amos CI, Felton S, Biggar RJ, Goedert JJ. Birth order, delivery route, and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twins. International registry of HIV-exposed twins. J Pediatrics. 1995;126:625–632
  18. Jamieson DJ, Cohen MH, Maupin R, Nesheim S, Danner SP, Lampe MA, et al. Rapid human immunodeficiency virus–1 testing on labour and delivery in 17 US hospitals: the MIRIAD experience. Am J Obstet Gynecol. 2007;197(3 suppl):S72–S82
  19. Schoen EJ, Limata C, Black SB. Unsuccessful voluntary prenatal testing for human immunodeficiency virus infection. Pediatr Infect Dis J. 2001;20:79–81
  20. Cohan D. Perinatal HIV: special considerations. Top HIV Med. 2003;11:200–213
  21. Zierler S, Witbeck B, Mayer K. Sexual violence against women living with or at risk for HIV infection. Am J Prev Med. 1996;12:304–310
  22. Loutfy M, et al. Maternikit. In: A reference guide for Health care professionals. 3rd ed.. Toronto, Ontario: Boehringer Ingelheim; 2006;
  23. Centers for Disease Control and prevention . Revised Guidelines for HIV Counselling, Testing and Referral. MMWR. 2001;50(RR19):1–57
  24. Public Health Service Task Force, (2007). Perinatal HIV Guidelines Working Group. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. [November 2, 2007].
  25. Butlerys M, Jamieson DJ, O'Sullivan MJ, et al. Mother Infant Rapid Intervention at Delivery (MIRIAD) Study Group. Rapid HIV 1 testing during Labour: a multi study Center. JAMA. 2004;292:219–223
  26. Minkoff H, O’Sullivan MJ. The case for rapid HIV testing during labor. JAMA. 1998;1743–1750
  27. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, Osullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type–1 with zidovudine treatment. N Engl J Med. 1994;3331:1173–1180
  28. Boucher M. Mode of delivery for pregnant women infected by the human immunodeficiency virus. SOGC. 2001;1–3
  29. Kuhn L, Stein ZA, Thomas PA, Singh T, Tsai WY. Maternal-infant HIV Transmission and Circumstances of Delivery. American Journal of Public Health. 1994;84:1110–1115
  30. Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev. 2005;19:CD005479
  31. American Academy of Pediatrics. Evaluation and Medical Treatment of the HIV Exposed Infant 1997;99:909-917.
  32. Hudson CN. In: HIV infection in obstetrics and gynaecology in Baillier’s Clinical Obstetrics and Gynaecology. 6(1):London: Bailliere Tindall; 1992;p. 137–148
  33. Report of the Committee on Infectious Diseases: The Red Book. Summaries of Infectious Diseases p. e335-e355.
  34. Hines S. Primary care for the HIV-exposed and infected children: translating progress into practice. Lippincotts Prim Care Pract. 2000;4:43–65
  35. CDC. MMWR Recommendations and reports. December 10, 1999;48(RR13):29-31.
  36. Horn T. Understanding your lab results. The body: the complete HIV/AIDS resource. Aids Community Research Initiative of Canada. 2004;www.thebody.comdownloaded February 20, 2007
  37. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951–1957
  38. Watts DH. Treating HIV during pregnancy: an update on safety issues. Drug Saf. 2006;29:467–490
  39. Chotpitayasunondh T, Vanprapar N, Simonds RJ, et al. Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus–infected mothers: Bangkok. Pediatrics. 2001;107:e5
  40. Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet. 1999;353:786–792
  41. Newell ML, Gibb DM. A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission. Drug Saf. 1995;12:274–282
  42. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281:151–157
  43. Ziegler JB, Cooper DA, Johnson RO, Gold J. Postnatal transmission of AIDS-associated retroviruses from Mother to Infant. Lancet 1: 1985. p. 896-898.
  44. Van de Perre P, Simonon A, Msellati P. Postnatal transmission of HIV type 1 from Mother to Infant: a prospective cohort study in Kigali, Rwanda. NEJM. 1991;325:593–598
  45. Rubini N, Passman L. Transmission of HIV infection from a newly infected mother to her 2 year old child by breastfeeding. Pediatric Infectious Disease Journal. 1992;11:682–683
  46. King SM. Evaluation and treatment of the human immunodeficiency virus-1–exposed infant. Pediatrics. 2004;114:497–505
  47. Clementson . Detection of HIV DNA in Cervical and Vaginal Secretions: Prevalence and Correlates among Women in Nairobi, Kenya. JAMA. 1993;269:2860–2864
  48. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between Nevirapine and ethinyl estradio/norethidrone when administered concurrently to HIV infected women. Journal of AIDS. 2002;29(5):471–477
  49. FLAVORx web site: http://www.flavorx.com. [Accessed 2/24/2008].
  50. Masur H, Kaplan JE, Holmes K. Guidelines for preventing opportunistic infections among HIV-infected persons—2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137(5 part 2):435–478

PII: S1527-3369(08)00082-2

doi: 10.1053/j.nainr.2008.06.008

Newborn and Infant Nursing Reviews
Volume 8, Issue 3 , Pages 136-143 , September 2008

Article Tools